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Abstract  
 
 Two independent projects oriented to synthesize naturally occurring compounds: 
a model of citreamicin θ A, and xanthocercin A with methoxy-butesuperin B. Citreamicin 
θ A was isolated from marine-derived bacteria Streptomyces caelestis and has been 
reported to possess antibacterial activity against multi-drug resistant Staph.aureus 
(MRSA). The key reactions in the multi-step synthesis of the citreamicin model 
compound involved a Sonogashira coupling and Diels-Alder cycloaddition. Xanthocercin 
A and methoxy-butesuperin B were isolated in a mixture with other chemical compounds 
from leadplant, Amorpha canescens. Due to the lack of material from natural sources, the 
structure and pharmaceutical properties of the compound can be confirmed only with the 
presence of an appropriate amount of the pure material. As part of ongoing efforts to fully 
verify the structure of the isolated natural products, we prepared a synthetic sample of 
both xanthocercin A and methoxy-butesuperin B. 
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1.0 Part I 
 
1.1 Introduction: 
 
 The search for bioactive natural products began hundreds of years ago.1 Natural 
products are chemical compounds that can be isolated from living organisms, such as 
plants, animals and microorganisms.1 Due to the chemical diversity and potential for 
biological activity, natural products have played an important role in pharmaceutical and 
agricultural research.2  
 The first purified antibiotic from a natural source was mycophenolic acid 1 
(MPA) discovered by Italian medical scientist, Bartolomeo Gosio, in 1893 (Figure 1).3 
Originally, MPA was used as an antibiotic against anthrax bacillus; however, due to the 
severe negative side effects and availability of other compounds associated with lower 
risks, MPA is not used as antibiotic anymore.4 Today, MPA is used as an 
immunosuppressive drug to prevent rejection in kidney, lungs, liver and bone marrow 
transplants5. Another more commonly known natural product is penicillin 2 (Figure 1), 
isolated from fungus Penicillium notatum in 1928.1  
  
Figure 1. The structure of mycophenolic acid 1 and penicillin 2 
 This discovery had an undeniable impact on medical practices since previously 
severe and often fatal infections, such as bacterial endocarditis, meningitis and 
pneumonia, could be easily treated. The discovery also affected chemical research by 
driving the efforts of scientists towards the discovery of novel antibiotics. Between 1940 
and 1980, thousands of microbial metabolites with a wide array of biological properties 
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have been discovered, such as streptomycin 3, tetracyclines 4, vidarabine 5 (Figure 2).1 
These compounds have been extensively used by pharmaceutical companies to prevent 
infections, and variety of viruses such as tuberculosis, skin infections and herpes.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Figure 2. Molecular structures of streptomycin 3, tetracyclines 4 and vidarabine 5 
Although the initial wave of microbial metabolites discovery has seemingly 
declined1, the recent appearance of antibiotic resistance increases the demand for the 
continuation of rapid discovery of new anti-infective metabolites.2  
To decrease the gap between the demand for new biologically active compounds 
and the rate of discovery of new natural products, many scientists have redirected their 
attention from terrestrial organisms to the marine environment.6 The ocean serves as an 
immense resource since it covers almost 70% of the earth’s surface and more than 90% 
of the crust’s volume. Such an environment is a potential source for countless new 
natural products, which have been a plentiful source for new pharmaceutical agents.1 
Furthermore, the diversity of marine organisms is immense compared with terrestrial 
organisms, demonstrating a high frequency of significant bioactivity. Approximately 1% 
of the tested marine samples showed anti-tumor potential in comparison to the 0.1% of 
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the tested terrestrial samples.6 Since the systematic investigations of marine environment 
began in 1970, a diverse range of biologically active agents displaying neurotoxic, 
antiviral, antitumor and cytotoxic have been discovered.7  
Therefore, marine bacteria continue to be primary candidates for chemical and 
clinical research due to the relative ease of cultivation and their ability to produce 
bioactive natural products.8 The initial challenge was to collect bacteria that dwell at 
greater depths in the ocean, since only a limited amount of bacteria lives in shallow 
water. Over the last several decades, advanced technology has opened new unexplored 
marine environments inhabited by marine life species.9 Giuseppe Brotzu was one of the 
first to isolate cephalosporin 6 from marine source Cephalosporium acremonium in 
1945.10 Cephalosporin is an antibiotic, which has a similar structure and properties to 
penicillin (Figure 3).  
  
Figure 3. Comparison of two structures penicillin 2 and cephalosporin 6 
 Most notably the natural products (Figure 3) share a ß-lactam ring, which 
covalently binds to the transpeptidase enzyme.  Transpeptidase enzymes cross link 
peptidoglycan to form the bacterial cell wall. The ß -lactam ring binds to the protein 
preventing the addition of new units to the peptidoglycan wall so that the structural 
integrity of the wall eventually fails leading to cell rupture and subsequent death of 
bacteria.11   
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In past decades, a methicillin-resistant Staphylococcus aureus (MRSA) has spread 
from hospitals to communities in many countries around the world. MRSA inhibits a 
gene mutation causing the production of protein PBP2a,12 which protects the bacterium 
from the binding of penicillin.13 Vancomycin 7 is an antibacterial isolated from 
Amycolatopsis orientalis and has been clinically used for the past fifty years to treat 
infections caused by Gram-positive bacteria, namely MRSA (Figure 4).14 However, the 
side effects of vancomycin can be severe, including liver damage and hearing loss, 
making it a drug of last resort. For this reason, there is a great need to find more natural 
products that will express biological activity against Gram-positive bacteria.  
 
Figure 4. Molecular structure of vancomycin 7 
The studies looking for alternative to vancomycin focus on citreamicin θ A and B 
(Figure 5) which are two new polycyclic antibiotics isolated from the marine-derived 
bacteria Streptomyces caelestis,15 which dwells in the Red Sea. 
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Figure 5. Structures of Citreamicin θ A 8 and B 9 
Citreamicin θ A 8 and B 9 have been reported to possess equal antibacterial 
activity against MRSA8 with a minimum inhibitory concentration (MIC) of 0.25 
µg/mL.15 In addition, citreamicin θ A and B have been reported to display antibacterial 
activity against a larger group of Gram-positive bacterium such as Staphylococcus 
aureus, Staphylococcus haemolyticus, and Bacillus subtillis.Error! Bookmark not 
defined. 
Citeramcins are polycyclic xanthones that share a common seven-ring system 
(5/6/6/6/6/6/6).Error! Bookmark not defined. The key structural moiety of both 
citreamicin θ A and B is a xanthone 10. Xanthones (Figure 6) are one of the largest 
classes of compounds in natural product chemistry, and the interest for its synthesis stems 
from their pharmaceutical characteristics. Traditional medicinal plants of the 
Gentianaceae family possess high presence of xanthones and are used to mediate loss of 
appetite and fever.16 Moreover, extracts from Swertia plant with high concentrations of 
xanthone-containing compounds have been reported to demonstrate insect repelling 
activity; the xanthonoid mangiferin, found in mango, displays anti-inflammatory effects; 
and xanthone extracted from S.paniculata have been used in treatment of some mental 
disorders.16  
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Figure 6. The structure of xanthone.  
In the lab, xanthones are usually synthesized via a reactions of benzophenones or 
dibenzyl ethers under harsh reaction conditions, often with the presence of strong acids or 
toxic metals.17As demonstrated below, a double C-H carbonylation reaction of 
benzophenone 11 in the presence of palladium catalyst can be used to form the xanthone 
ring system 12 (Scheme 1). However, various other approaches have been investigated 
and can be used to synthesize xanthone-encompassing molecules.  
Scheme 1. Pd-Catalyzed oxidative carbonylation to synthesize xanthone 1218 
  
Another common approach to the synthesis of xanthones relies on a base-
catalyzed cyclization reaction to produce 3,6-dihydroxyxanthone 13 (Scheme 2).19 The 
heating of 2,2’,4,4’tetrahydroxybenzo-phenone 13 in a furnace to 180˚C caused loss of 
water and 85% conversion to 3,6-dihydroxyxanthone 14.17 
Scheme 2. Common way to synthesize xanthones  
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An example of efficient xanthone derivative synthesis was presented by Zhan-Hui 
Zhang in 2009.20  A one-pot three-component reaction of 2-naphthol 15, aldehydes 16, 
and cyclic 1,3-dicarbonyl compounds 17 carried out in the absence of solvent was 
catalyzed with NaHSO4•SiO2.20 The reaction proceeds via the Michael addition of 
aldehyde to naphthol and dicarbonyl compounds with the use of HBF4/SiO2 (Scheme 3). 
Scheme 3. Preparation of xanthenone derivatives under solvent-free conditions21 
 
A less common one-pot reaction approach to synthesize xanthone by 
intermolecular trapping pathway was also described in the literature. Benzyne 22 was 
formed by reacting o-(trimethylsilyl)phenyl triflate 20 in the presence of cesium fluoride 
(Scheme 4).17 Most importantly, trapping the unstable benzyne with methyl salicylate 19 
forms the final xanthone skeleton 23.  
Scheme 4. One-pot synthesis of xanthones 
 
Our studies focused on a novel approach for the synthesis of xanthones utilizing a 
hexadehydro-Diels-Alder reaction (HDDA).22 HDDA is a reaction between a 1,3-diyne, 
which is engaged in a [4+2] cycloisomerization with a ‘diynophile’ to produce the highly 
reactive benzyne intermediate.22 Our approach for the synthesis of citreamicin θ A 8 and 
B 9 was based on the Hexadehydro-Diels-Alder reaction (HDDA)22 followed by 
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intramolecular trapping of the resulting aryne 25 with methyl salicylate 19 (Scheme 5). 
Formation of aryne 25, a cyclic compound with a triple bond, occurs by the mechanism 
in the hexadehydro-Diels-Alder reaction where by the triple bond acts as a nucleophile to 
form a C-C bond with electrophilic carbonyl of methyl salicylate (Scheme 5). 
Scheme 5. Hexadehydro-Diels-Alder reaction and intramolecular trapping to form 
xanthone model molecule.  
 
  
The target molecule 26 (Figure 7) forms the main core of citreamicin θ A and B. 
In comparison to the seven-ring system in citreamicin θ 8, xanthone 26 is a five-ring 
system lacking the functional groups, its preparation will serve as a proof of concept to 
show the advantages of this approach. The other rings and functional groups are 
compatible with this process and can be places in later stages of the synthesis.  
  
Figure 7. The structure of citreamicin θ A and the model system target 26  
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1.2 Retrosynthesis: 
The synthetic approach taken to synthesize xanthone 26 revolved around two key 
reactions. The key step in a model compound formation is the hexadehydro-Diels-Alder, 
which was anticipated to form the tricyclic reactive benzyne 25 (Scheme 6). Once 
formed, benzyne 25 was expected to undergo a rapid addition with methyl salicylate 19. 
The required starting material for the final Diels-Alder step, bis-
trimethylsilyl(TMS)alkyne 24 was synthesized by means of Sonogashira coupling of 
TMS-butadiyne 29 with the aryl bromide 28 and alkylation of the benzylic bromide with 
TMS-propyne 27.    
Scheme 6. Retrosynthesis of citreamicin θ A model 
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1.3 Results and Discussion:  
The multistep process of synthesizing the target xanthone 26 began with Glaser 
coupling in order to synthesize 1,4-bis(trimethylsilyl)-1,3-butadiyne 32 (Scheme 7). 
Glaser coupling is the preparation of linear or cyclic bisacetylenes via oxidative homo 
coupling of terminal alkynes in the presence of copper salt.23 For this synthesis, the 
conditions developed by Hey in the presence of the bidentate ligand 
tetramethylethylenediamine (TMEDA) 31 were used to create a copper complex. The 
advantage of this modification is increased solubility of the resulting complex, which 
makes the reaction more adaptable to variable conditions and solvents.23 
Scheme 7. Net reaction equation for the synthesis of 1,4-bis(trimethylsilyl)-1,3-butadiyne 
32 
 
  
The procedure24 was closely followed the first time and a high yield of 80% was 
obtained. The original procedure involves a use of oxygen gas, which is a fire hazard 
when used with volatile solvents such as acetone. Since large volumes of acetone were 
used for the big scale reactions to synthesize bis-TMS 32, several modifications were 
made to simplify the procedure and reduce the potential hazard.  
The first modification involved the preparation of catalyst complex under room 
conditions open to air. The copper compound was not forming a complex with TMEA; 
instead it was oxidizing to a lower energy copper oxide. Therefore, a decision to prepare 
catalyst mixture under inert conditions in the presence of nitrogen was made.  
Second, oxygen gas was removed from the system. Instead of using oxygen, a 
stream of air was bubbled into the reaction flask. The disadvantages of the modification 
TMS TMS TMSO2 CuCl
30
H N N+
80%
Air 35-65%
3231
	 11	
include the decrease of yield since trimethylsilylacetylene 30 and acetone were 
evaporating prior to coupling due to excessive flow of air. Another possible reason for 
evaporation is the high volatility of trimethylsilylacetylene 30 and the incomplete 
preparation of the catalyst, which can prevent the formation of product.  
As result of systematic condition variation, it was determined that the copper 
catalyst should be prepared in a closed system under nitrogen to avoid the formation of 
copper oxide and allow TMEDA 31 to form the copper complex. Substituting oxygen gas 
with air decreased the reaction yield to 35-65%. With the moderate flow of air acceptable 
yields were obtained, and the decision to carry out this modified procedure was made as 
it reduces the risk of ignition. 
The Glaser coupling reaction was followed by the synthesis of 1,3-
butadiynyl(trimethyl)silane 29 from the trimethylsilylacetylene 32 (Scheme 8). The 
desilylation of the TMS group was carried out in the one-step reaction of TMS-alkyne 32 
with methyl lithium in anhydrous ether. Initially, the ratio of methyl lithium to TMS-
alkyne 32 used was 1:1 to avoid formation of 1,3-butadiyne as a result of cleaving both 
TMS groups; however, the complete conversion of the starting material to product 29 was 
not achieved. In order to increase the yield, the ratio of methyl lithium to bis-TMS 32 was 
altered from 1:1 to 1:1.5. The conversion to the desired butadiynyl-TMS 29 increased to 
60%. The purification of the mixture and isolation of compound 29 was accomplished by 
vacuum distillation, affording a clear, colorless liquid that changed color to yellow once 
exposed to air.  
 Scheme 8.  The net reaction equation to synthesize 1,3-Butadiynyl(trimethyl)silane 29  
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The alkylation reaction began with reaction of 2-bromobenzyl bromide 28 and 
TMS-propyne 27. The reaction yield 97 % of relatively pure crude bromine 34 (Scheme 
9).  
Scheme 9. Alkylation reaction pathway  
 
Sonogashira coupling is a reaction discovered by Kenkichi Sonogashira and 
coworkers in 1975.24 Before the discovery of the first transitional metal catalyzed 
coupling reaction, benzyl halides were known to undergo addition-elimination, SRN1, or 
elimination-addition reactions. The Kumada reaction was the first substitution of benzyl 
halide with Grignard reagent performed at room temperature and catalyzed by a Ni 
complex. The discovery of Kumada reaction encouraged the search for new metal-
catalyzed reactions.25 Processes such as the Stille, Suzuki and Sonogashira reactions are 
few of the common ways to form new C-C bonds that are widely used today for synthetic 
purposes.   
Sonogashira coupling of terminal alkynes with aryl or vinyl halides requires the 
presence of a palladium catalyst, an amine base and a copper(I) co-catalyst24 along with 
anhydrous and anaerobic conditions. The catalytic cycle for every reaction involves five 
key steps: oxidative addition, coordination, insertion, transmetallation and reductive 
elimination (Scheme 10).25  
Once the Pd(0) complex (a) has entered the catalytic cycle, the first step is 
initiated by oxidative addition of the aryl halide (b), which is considered to be the rate-
limiting step of the Sonogashira reaction.26 The rate of addition depends on the nature of 
the halogen, and it was proven to increase with the increase of the halogen size 
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(I>Br>Cl).26 The possible explanation to the phenomenon is that the end-on ligation is an 
electron donating step. Therefore, the higher the EHOMO of the substrate, the more stable 
the palladium complex (c).26  
Scheme 10. Key steps of transitional metal catalytic cycle  
 
In order to improve reaction outcomes, such as purity, yield and efficiency of the 
reaction, conditions are often varied to determine the appropriate system for the coupling 
of interest. Commonly altered conditions include the type and amount of catalyst. 
Traditionally used catalysts are triphenylphosphine-complexes, with the most common 
and soluble version being Pd(PPh3)2Cl2 (I).27 Common bidentate ligands used for 
Sonogashira reaction include Pd(dppe)Cl2 (II), Pd(dppp)Cl2 (III), and Pd(dppf)Cl2 (IV) 
(Scheme 11). 
Scheme 11. Structures of Pd(PPh3)2Cl2 (I), Pd(dppe)Cl2 (II), Pd(dppp)Cl2 (III), and 
Pd(dppf)Cl2 (IV) 
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Numerous attempts to couple aryl bromide 34 with the butadiynyl-TMS 29 and 
the terminal alkyne 30 were made (Scheme 12). Conditions such as starting material, 
solvent system, catalyst type and load, temperature, and reaction time were varied to 
achieve reasonable coupling yields (Table 1). The decision to change the terminal alkyne 
from the butadiynyl-TMS 29 to a simplified alkyne 30 was made since the initial attempts 
to couple butadiynyl-TMS 29 failed to yield any products. The simplified model with the 
terminal alkyne 30 should demonstrate similar coupling rated to butadiynyl-TMS 29 
since both molecules have TMS and alkyl functional groups. The use of commercially 
available terminal alkyne 30 allowed for the creation of more variations of reaction 
conditions without additional multi-step synthetic preparations as butadiynyl-TMS 29 
would require.  
Scheme 12. Sonogashira coupling with benzyl bromide  
 
 However, none of the attempts yielded high coupling outcomes. The reaction 
conditions reported in one entry (DR-I-22) coupled only 60% of starting aryl-bromide 
(Table 1).   
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 Table 1. Reaction table for Sonogashira coupling with aryl iodide  
Entry Starting 
Material 
Eq. Catalyst Solvent Temp. Time Conclusion 
DR-I-
10 
Alkyne 
29 
Bromide 
34 
1 
 
1 
DPPF 
(4%) 
CuI (10%) 
THF RT 26h 1HNMR No 
product formed 
DR-I-
12 
Alkyne 
29 
Bromide 
34 
1 
1 
DPPF 
(4%) 
CuI (10%) 
Acetonitrile RT 
60˚C 
3h 
30mi
n 
1HNMR No 
product formed 
DR-I-
18 
Alkyne 
29 
Bromide 
34 
2 
 
1 
PdCl2(PPh
3)2 (7%) 
CuI (7%) 
Toluene 80-
85˚C 
4h 1HNMR No 
product formed 
DR-I-
24 
Alkyne 
29 
Bromide 
34 
4 
 
1 
DPPF 
(7%) 
CuI (7%) 
Toluene 80-
85˚C 
3.5h 1HNMR No 
product formed 
DR-I-
13 
Alkyne 
30      
Bromide 
34 
1 
 
1 
DPPF 
(5%) 
CuI (7%) 
Acetonitrile 60˚C 24h 1HNMR No 
product formed 
DR-I-
15 
Alkyne 
30 
Bromide 
34 
1 
 
1 
DPPF 
(5%) 
CuI (7%) 
Acetonitrile RT 48h 1HNMR No 
product formed 
DR-I-
16 
Alkyne 
30      
Bromide 
34 
2 
 
1 
PdCl2(PPh
3)2 (7%) 
CuI (7%) 
Toluene 85-
90˚C 
3h 1HNMR 2:1 
starting 
material to 
product  
DR-I-
20 
Alkyne 
30      
Bromide 
34 
2 
 
1 
DPPF 
(7%) 
CuI (7%) 
Toluene 
 
80-
85˚C 
3h 1HNMR: 
Presence of 3 
TMS group 
and coupled 
product is 1:1 
DR-I-
22 
Alkyne 
30      
Bromide 
34 
4 
 
1 
DPPF 
(7%) 
CuI (7%) 
Toluene 80-
85˚C 
3.5h 1HNMR  
60%:40% 
coupled 
product to 
starting 
material  
DR-I-
25 
Alkyne 
30      
Bromide 
34 
4 
 
1 
DPPF 
(7%) 
CuI (7%) 
Toluene 90˚C 3.5h 1HNMR  
1:1 product to 
starting 
material 
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The Sonogashira coupling is one of the key reactions for the synthesis of 
xanthone 26. High yields and purity of the coupling reaction were necessary to continue 
the sequence of reactions. Therefore, a decision was made to change starting aryl-
bromide 34 to the more reactive aryl iodide 36. In order to carry out the Sonogashira 
coupling with TMS-iodode 37, a previously described alkylation reaction was performed 
using 2-iodobenzyl bromide 36 (Scheme 13).  
Scheme 13. Alkylation reaction of using 2-iodobenzyl bromide 36 with TMS-alkyne 27.    
 
An initial attempt to alkylate aryl iodide 36 with TMS-27 did not yield desired 
product as only starting material was detected by 1HNMR. The difference between the 
reactivity of aryl bromide 28 and aryl iodide 36 is due to the nature of halogen. Since the 
alkylation reaction proceeds by the SN2 mechanism, the TMS nucleophile 33 was 
constant for both alkylation reactions with aryl iodide 36 as well as aryl bromide 28. 
Therefore, the nature of electrophile was the reason for significant decrease in the 
reactivity. Since iodide is larger and less electronegative than bromide, steric effect is the 
reason for differences in alkylation, which can explain an absence of alkylation reaction 
between aryl iodide 36 with TMS 27.  
 The nucleophile had to be altered for the alkylation to occur with the iodide 36. 
An alternative to TMS acetylene 27 was the more stable triisopropylsilyl (TIPS) 
acetylene 38 (Scheme 14). The alkylation reaction between aryl iodide 36 and alkyl 38 
initially produced 30% of aryl iodide 40. In order to increase yield, the formation of 
anion was carried out at -78˚C, after which the reaction mixture was warmed up to 0˚C to 
kinetically speed up the deprotonation and form the corresponding propargyl anion 39. 
H3C TMS TMS
I
Br
I
TMS
27 33 36 37
BuLi
THF -78˚C + THF
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The addition of 2-iodobenzylbromide 36 was performed at -78˚C to avoid additional 
alkylation reaction that earlier caused formation of a side product. These manipulations 
increased the conversion, giving a 2:1 ratio of product to starting material.  
Scheme 14. Alkylation reaction of using 2-iodobenzyl bromide 36 with TIPS-alkyne 38 
 
In order to purify iodide 40, a benzyl bromide alkylation reaction with pyrrolidine 
was performed. The Rf values of benzyl bromide 36 and alkyne 40 were too close to each 
other to be separated. In addition, the compounds are too non-polar for the FLASH 
chromatography separation; therefore, a decision of adding the pyrrolidine ring 41 to 
remaining 2-iodobenzylbromide 36 and changing the polarity of starting material was 
made (Scheme 15). The earlier synthesized mixture of benzyl bromide 36 and alkyne 40 
was used in the reaction with pyrrolidine 41 to isolate alkyne 40 from the mixture. 
Extraction was done using HCl (10%) to protonate pyrrolidine 42, which was extracted 
into the aqueous layer while the desired product 40 remained in the organic phase. The 
purification of compound 40 was followed by Sonogashira coupling. 
Scheme 15. Replacement of bromide with pyrrolidine  
 
The synthesis of TIPS-iodide 40 was more challenging than that of the 
corresponding TMS-bromide 34. Specifically, the alkylation reaction yielded less desired 
product and additional purification was necessary to isolate TIPS-iodide 40. The iodide 
compound was needed for Sonogashira coupling to continue the sequence. 
H3C TIPS TIPS
I
Br
I
TIPS
38 39 36 40
BuLi
THF -78˚C + THF
60%
I
Br
N
H
I
N
36 41 42
+ +
I
TIPS
40
+ MeCN80˚C
I
TIPS
40
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With TIPS-iodide 40 and butadiynyl alkyne 29 in hand, the next task was the 
Sonogashira coupling (Scheme 16).  
Scheme 16. Sonogashira coupling of aryl iodide 40 and butadiynyl alkyne 29   
 
For this synthesis project, multiple reaction conditions were used for coupling: the 
solvent systems, catalyst, concentrations and temperatures were varied (Table 2). Optimal 
conditions for the reaction were determined: room temperature, 1:3 ratio of TIPS-iodide 
40 and butadiynyl-TMS 29 respectively, 10% tetrakis(triphenylphosphine)palladium(0) 
(added in 2 increments), 16% CuI co-catalyst loading (added in 2 increments), and 
diisopropylamine that was used in the reaction as a solvent and as a base. The reaction 
ran to completion if was left to run overnight. The product was used for hexadehydro 
Diels-Alder reaction with a xanthone trapping.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
TIPS
TMS H
TIPS
TMS
Pd(0),CuI+
40 29 43
84%
N
H
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Table 2. Reaction conditions used for Sonogashira coupling of aryl iodide 40 and 
terminal alkyne 
 
Entry Starting 
Material 
Eq. Catalyst Solvent Temp
. 
h Conclusion 
DR-I-
26 
Alkyne 
30      
Iodide 
40 
4 
 
1 
DPPF (10%) 
CuI (10%) 
Toluene 80-
85˚C 
3.5h 1HNMR the 
product 
formation 60% 
product to 
40% starting 
material 
DR-I-
31 
Alkyne 
30      
Iodide 
40  
4 
 
1 
PdCl2(PPh3)2 
(10%) 
CuI (10%) 
THF RT 48h The 
concentration 
of the sample 
was not 
enough to 
obtain spectra. 
DR-I-
54 
Alkyne 
29 
Iodide 
40 
1.5 
 
1 
DPPF (7.5%) 
CuI (3.5%) 
Toluene RT 2h 1HNMR: No 
coupled 
product only 
presence of 
TMS dimer 
DR-I-
55 
Alkyne 
29  
Iodide 
40 
2 
 
1 
DPPF (16%) 
CuI (46%) 
Toluene RT 2h 1HNMR: No 
coupled 
product only 
presence of 
TMS dimer 
DR-I-
58 
Alkyne  
29 
Iodide 
40 
1 
 
 
1 
PdCl2(PPh3)2 
(5,5%) 
CuI (8%) 
Diisopro
pylamine 
RT 24h 1HNMR: 
starting 
material to 
coupled 
product (1:2) 
TLC also 
indicated 
presence of 
dimer 
DR-I-
65 
Alkyne 
29  
 
Iodide 
40  
 
1.5, 
 
 
0.51 
 
PdCl2(PPh3)2 
(5,6%) 
CuI 
(10,11%) 
Diisopro
pylamine 
RT 24h Silica 
purification 
1HNMR: 
48.8% yield 
 
 
DR-I-
70 
Alkyne 
29 
 
Iodide 
40 
1.5, 
1.5 
 
1 
PdCl2(PPh3)2 
(5,6%) 
CuI (10,9%) 
Diisopro
pylamine 
RT 24h Silica 
purification 
1HNMR: 84% 
yield 
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The final step for this project was to synthesize three-ring intermediate benzyne 
25 and trap it with methyl salicylate 19 to form xanthone 26. The initial TIPS-TMS- 
trialkyne 43 used for the reaction was a ring molecule with a three triple bond system and 
TIPS, TMS groups attached to the triple bonds (Figure 8).  
  
Figure 8. The compound used for the Diels-Alder reaction 
The Diels-Alder reaction is an electrocyclic reaction that involves 4 π-electrons of 
the diene and 2 π-electrons of the dienophile. The formation of two new σ-bonds is the 
driving force of the reaction since they are energetically more stable than the π-bonds. 
The most highly oxidized Diels-Alder reaction include the hexadehydro-Diels-Alder, the 
cycloaddition between 1,3-diyine and an alkyline diynophile 44, which generates o-
benzyne, a highly reactive species, that rapidly reacts in intra- or intermolecular trapping 
(Scheme 17).  
The hexadehydro-Diels-Alder reaction is a relatively new reaction, which has not 
been extensively studied; however, the reactions presented in the literature have 
promising outcomes, high yields under moderate conditions (Scheme 17). The HDDA 
reaction with single regiochemical outcome used to synthesize tetracyclic indenone 
derivative 45 was successful at room temperature to form a six membered aromatic 
ring.22 
 
 
 
 
TIPS
TMS
43
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Scheme 17. HDDA reaction to synthesize tetracyclic indenone derivative 45  
  
This reaction involved formation of benzyne intermediate and intermolecular 
trapping of benzyne with the oxygen, which it attached to S-benzylthiuronium (SBT) 
functional group.  
Ortho-benzyne 47 is one of the earliest identified and most studied intermediates. 
Benzyne has long been used in synthetic chemistry due to the ease of formation and high 
reactivity of the intermediate. The most common method to synthesize benzyne 47 
involves the removal of two adjacent atoms or functional groups from a benzenoid 46 
predecessor (Scheme 18). These methods typically require use of a strong base and or 
acid. 
Scheme 18. Formation of o-Benzyne and Trapping 
 
The hexadehydro-Diels-Alder reaction is an alternative reaction for the formation 
xanthone natural products by generation of unstable benzyne intermediate that is 
followed by the intermolecular trapping mechanism. 
The reaction of TIPS-TMS trialkyne 43 with methyl salicylate 19 was performed 
at 65 ˚C (THF), 100 ˚C (toluene), and 130 ˚C (xylenes), none of which led to xanthone 50 
formation (Scheme 19). Diels-Alder reaction did not proceed since both starting materials 
were present upon 1HNMR spectral analysis.  
O
TMS
OSBT
CDCl3 26˚C
46h
O
O TMS
TBS
44 45
93%
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El
X
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G X
Nu
El46 47 48
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Scheme 19. Hexadehydro-Diels-Alder reaction of TIPS-TMS-alkyne 43 with methyl 
salicylate trapping 
 
 
A potential explanation could be the steric hindrance caused by TMS and TIPS 
groups, which would not allow the triple bonds in close enough proximity to each other 
for reaction. To test this hypothesis, the TMS group was removed from TIPS-TMS 
trialkyne 43 using K2CO3 in methanol as a solvent to provide a terminal TIPS-alkyne 51 
(Scheme 20).  
Scheme 20. Cleavage of TMS group from TIPS-TMS alkyne 43 
 
  
 
TIPS-alkyne 51 without a TMS group was used to perform a hexadehydro Diels-
Alder reaction under following conditions 65 ˚C (THF), 100 ˚C (toluene), and 130 ˚C 
(xylenes). No product formation was observed, and starting materials were still present in 
the reaction mixture according to the 1HNMR (Scheme 21). 
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Scheme 21. Hexadehydro-Diels-Alder reaction of TIPS alkyne 51 with methyl salicylate  
 
  
Finally, both TMS groups were cleaved from di-TMS-alkyne 24 using potassium 
carbonate in methanol to form tri-alkyne 54 (Scheme 22). 
Scheme 22. Cleavage of TMS groups from di-TMS-alkyne 24  
 
 
 
 This modification yielded the least hindered alkyne model out of all previously 
tested for the hexadehydro-Diels-Alder reaction. As before, the conditions used were 65 
˚C (THF), 100 ˚C (toluene), and 130 ˚C (xylenes). The 1HNMR no presence of xanthone 
56 and shows only the sole presence of starting materials (Scheme 23).  
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Scheme 23. Hexadehydro-Diels-Alder reaction of tri-alkyne 54 with methyl salicylate 
 
 
1.4 Conclusion  
 
 The goal of this project to synthesize a cascade for citreamicin θ A and B was 
never reached. The final and key step to synthesize a molecule containing five ring 
system though Diels-Alder reaction has not worked. However, several precursor 
compounds that were prepared for Diels-Alder cyclization reaction were prepared for the 
first time such as tri-alkyne 54, di-TMS-alkyne 24, TIPS-alkyne 51, and TIPS-TMS 
trialkyne 43.  
 For the future studies an electron withdrawing group can be placed at the end of 
alkynes. This modification has a potential to increase the reactivity of diyenes because 
reactive species presented in the original hexadehydro-Diels-Alder reaction in the 
literature contained carbonyl or other electron withdrawing groups. Another possible 
modification can be a placement of a sterically hindering groups on propargylic carbon in 
order to decrease free rotation of diyene about a single bond and decrease the distance 
between diyenes.  
 
 
 
 
 
 
 
 
O
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2.0 Part II Total Synthesis of Xanthocercin A and Methoxy-butesuperin  
 
2.1 Introduction:  
 
The chemistry of natural products originates in 18th century from the work of the 
apothecaries and pharmacists of the time. German chemist Fredrich Wöhler was one of 
the most prominent scientists in the field. He synthesized urea 59 in 1829 through the 
addition of silver cyanate 58 to ammonium chloride 57 solution (Scheme 24).28  
Scheme 24. Synthesis of urea 
 
 
 
The discovery of urea changed the direction of organic synthesis, as scientists 
originally believed in “vitalism,” a theory that natural products can only come from 
natural sources.29 Wöhler’s discovery proved that humans were made from the same 
chemical composition as the world around us, since the synthesized organic compound 
was from two inorganic substances. The chemical synthesis of urea was one of the factors 
that contributed to the development of natural products total synthesis.  
Total synthesis is defined in literature as the chemical synthesis of complex 
molecules, usually natural products, from relatively simple starting materials.30 Today, 
there are multiple reasons driving organic chemists to pursue total synthesis. Some wish 
to use the structure of the molecule as an opportunity to discover and develop new 
reactions. Others may wish to develop a relatively more easy and efficient way of 
producing biologically active natural products. In addition, total synthesis provides an 
opportunity for education and training in problem solving skills, critical thinking and 
logical reasoning.31 Enterprise in total synthesis can enhance different levels of challenge 
depending of the complexity of the molecule and the chosen synthetic approach. Slight 
57 58 59
NH4Cl + AgNCO
O
H2N NH2
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modifications in the stereochemistry or functional groups often influence not only the 
synthetic pathway but also the biological activity of the molecule of interest. 
The goal of this project was to synthesize xanthocercin A 60 and its proposed 
derivative, which we are tentatively calling methoxy-butesuperin B 61 – both are 
naturally occurring isoflavones (Figure 9). 
 
 
Figure 9. Structure of xanthocerin A 60 and analogue 61 
 
 Isoflavones are phytoestrogens ie. plant derived compounds exhibits estrogenic 
activity. Compared to estrogen, isoflavones are not produced by endocrine systems, but 
can act as an estrogen. Therefore, they are beneficial when consumed in the dietary sense. 
More than 300 kinds of plants, especially roots and seeds, have been found to contain 
isoflavones.32 The structure of isoflavones composed of a 3-phenylchromen-4-one 
skeleton 62 (Figure 10).25  
 
Figure 10. The structure of isoflavone skeleton  
 
Isoflavones are similar to 17-ß-estradiol 64 as they are diphenolic, non-steroidal 
estrogens (Figure 11) though the exact part of the molecule that is responsible for binding 
is unknown. In an attempt to understand mechanistic pathways, scientists actively have 
investigated a variety of isoflavones and β-estradiol. Due to similarities in structure, 
HO
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isoflavones demonstrate biological activity in such that they can act as estrogen agonists 
or antagonists depending on the chemical structure of functional groups and the 
metabolism mechanism.Error! Bookmark not defined. A possible reason for the similar 
activity of isoflavones and 17-ß-estradiol is the presence of two similarly placed phenol 
functional groups and the overall shape of the compounds.  
 
 
 
 
Figure 11. Structures of isoflavone 63 and β-estradiol 64 
 
Similar to 17-ß-estradiol, some isoflavones can bind to estrogen receptor (ER), 
particularly to the ER-α and ER-ß. The similarities in structure with 17-ß-estradiol not 
only allow isoflavones to bind with receptors, but also to have a potential effect on 
intercellular signaling mechanism such as cellular growth and protection.33  
It is known that the concentration of two ER receptors varies in different organs 
and parts of the body. For example, breasts, ovaries, and uterus have high concentrations 
of ER-α. In contrast, the expression of ER-ß is high in prostate, kidneys, bladder, lungs 
and bones.33 The need to develop synthetic methods to generate isoflavones is high since 
the material is used to confirm isolated plant conjugates and their human metabolites. In 
addition, metabolites are necessary for the testing of the possible biological activity of the 
identified compounds.34 
The most common source of isoflavone in the human diet is soy. In soy beans, 
isoflavones are bound to a sugar molecule. Once soy products are fermented or digested, 
the sugar molecule is released from glycosides, leaving the free isoflavone. Genistein 65, 
O
O OH
HH
H
CH3HOR3HO
R2
R1 OH
63 64
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daidzein 66, and glycitein 67 are few of the most commonly present isoflavones in 
soybeans (Figure 12). Other products with high concentrations of isoflavone compounds 
are kudzu, lupine, broccoli, cauliflower, barley, and fava beans.34 
 
 
 
Figure 12. Molecular structures of genistein 65, daidzein 66, and glycitein 67 
 
The beneficial health effects of isoflavones have long of scientific interest 
encouraging the study and synthesis of these compounds. One main interest is the tissue-
selective activities of isoflavones since they demonstrate both estrogenic and anti-
estrogenic activity. Estrogenic activity of isoflavones helps maintain bone mineral 
density and improve blood lipid profiles, while anti-estrogenic activity helps prevent the 
release of cancer causing hormones. The positive correlation between the consumption of 
isoflavones and prevention of cancer, osteoporosis and cardiovascular diseases have been 
presented and heavily investigated in recent years.33  
 Dr. Tristesse Burton of the University of Illinois at the Chicago Botanical Center 
isolated two compounds assumed to be xanthocerin A 60 and methoxy-butesuperin B 61 
in a mixture with other chemical compounds from Amorpha canescens, known as 
leadplant (Figure 13). The leadplant plant was selected due to its traditional use by Native 
Americans as an anti-inflammatory and anti-rheumatic medication. The leadplant was 
one out of 164 potential candidates that were selected and extracted with methanol for 
screening in biological assays.  
Xanthocerin A was tested using bioassay-guided fractionation targeting the ES- α, 
O O OHO
OOH OH O OH
HO
O
HO
H3CO
OH
65 66 67
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and this extracted fraction was found to be active in anti-inflammatory and anti-rheumatic 
assays.  
 
 
 
 
 
 
 
 
Figure 13. Amorpha canescens 
 
The quantity of the extracted xanthocerin A 60 and methoxy-butesuperin 61 from 
the plant were not sufficient to run all necessary analyses in order to confirm the structure 
of the biologically active components. In order to extract biologically active chemical 
compounds, plants are crushed and extracted with organic solvents, and after multiple 
separations oftentimes only small amounts of organic compounds can be isolated for 
spectroscopic analysis. Additionally, the low purity of isolated compounds complicated 
the structural analysis. The isolated mixtures often have congeners, which make it 
difficult to identify novel structures, without available literature spectra. Finally, 
difficulties that are due to the inherent structure of natural compounds e.g. placement of 
an isolated methoxy group can make assigning the correct positions of protons in the 
NMR spectrum onto the structure. Due to the mentioned reasons, it was advantageous to 
obtain sufficient quantities of pure material for complete analysis.  
In order to prove that the isolated materials were indeed xanthocercin A 60 and 
methoxy-butesuperin 61, it was necessary to obtain enough material via total synthesis to 
complete the analytical comparison with the isolated compounds.  
	 30	
2.2 Retrosynthesis  
 
The key step in the synthesis xanthocerin A 60 is an oxidative coupling of 
isoflavone 69 with sinapyl alcohol 68 in the presence of silver oxide.35 Isoflavone 69 was 
prepared by reacting phenyl benzyl ketone 70 with trichloro-triazine in 
dimethylformamide (Scheme 25).36  
Scheme 25. Scheme of the retrosynthesis of xanthocerin A 
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2.3 Results and Discussion  
 
Xanthocercin A 60 was isolated from Xanthocercis zambesiace and derivatized in 
1988 by S.C.Bezuidenhout.35 The interest in xanthocercin A was related to its potential 
biological activity and interesting chemical structure. Xanthocercin A was the first 
isolated isoflavone containing a 1,4-dioxane fragment fused to the isoflavone ring.37 
Since isoflavones similar to xanthocercin A have been synthesized before, the reactions 
presented in literature were utilized and modified to obtain enough material for 
spectroscopic analysis.  
The synthesis of xanthocercin A began with the reaction of commercially 
available pyrogallol 71 and phenylacetic acid 72 in boron trifluoride diethyl etherate 
(BF3OEt2) to yield 7,8-dihydroxy-3-(methoxyphenyl)-4H-chromen-4-one 70 (Scheme 
26).36 The product was extracted from the reaction mixture to yield 70% of crude 
chromenone 70 as a small amount of starting acetic acid 69 was present in the reaction 
mixture. 
Scheme 26. Synthesis of 7,8-dihydroxy-3-(methoxyphenyl)-4H-chromen-4-one 
 
 
 
Chromenone 70 was used for the synthesis of isoflavone 69 in the second step of 
the synthesis. Several different approaches found in the literature were attempted to 
compare the yield and purity of the produced isoflavone 69 (Table 3). The room 
temperature reaction in the presence of cyanuric acid (TCT)38 yielded the purest product 
with the crude yield 75%. 
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Scheme 27. Net reaction to synthesize isoflavone compound 69 
 
 
Table 3. Reaction summary to synthesize iosflavone 69  
 
Entry Reactant  Equivalents  Condition Conclusion 
1 
 
Chromenone 70 
DMF-DMA 
1 
6 
2 min 
microwave at 
60˚C 
Incomplete reaction with 
presence of four major 
impurities. 
2 
Chromenone 70 
DMF-DMA 
1 
10 
10 min 
microwave at 
60˚C 
TLC analysis revealed 
presence of seven impurities 
in the crude mixture 
3 
Chromenone 70 
DMF-DMA 
1 
9 
Room 
temperature 
Formation of products and 
major impurities as well as 
unreacted starting material 
were detected by TLC 
4 Chromenone 70 TCT 
1 
1.5 
30 min, 60˚C NMR suggests pure product 
with minor impurities  
  
 With isoflavone 69 in hand, the second part of the synthesis involved preparation 
of sinapyl alcohol 68. The synthesis of the sinapyl alcohol began with the Knoevenagel 
reaction between syringaldehyde 73 and malonic acid 74 to yield white crystalline sinapic 
acid 75 in 91% yield (Scheme 28).39  
Scheme 28. Synthesis of sinapic acid 75 
 
  
 The next step in this synthesis involved a Fischer esterification reaction of sinapic 
acid 75 to yield methyl sinapate 76 (Scheme 29).Error! Bookmark not defined. The 
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HCl acid catalyst for this reaction was produced in situ by adding thionyl chloride into 
methanol and refluxing the sinapic acid 75 in this media.  
Scheme 29. Synthesis of methyl sinapate 76  
 
 
 
Methyl sinapate 76 was reduced to a sinapyl alcohol 68 through the use of lithium 
aluminum hydride that had been modified with butyl bromide (Scheme 30).Error! 
Bookmark not defined. Sinapyl alcohol is sensitive to air and an easily decomposable 
compound, therefore the freshly prepared alcohol 68 was immediately used in the 
coupling reaction with isoflavone 69.  
Scheme 30. Synthesis of sinapyl alcohol 68 
 
Having obtained the two required compounds, isoflavone 69 and sinapyl alcohol 
68, xanthocercin A 60 was synthesized via an oxidative coupling reaction. Barton and 
Cohen initially described phenolic oxidative coupling in the literature in 195740 whereby 
the presence of oxidants such as silver salt can be used to form carbon-carbon or carbon-
oxygen bonds.41 The final and key step of this project involved such an oxidative phenol 
coupling, which was carried out in the presence of freshly prepared silver oxide catalyst 
obtained, in turn, from the reaction of sodium hydroxide and silver nitrate (Scheme 31).  
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Scheme 31. Oxidative coupling of isoflavone 69 and sinapyl alcohol 68    
 
 As expected, the reaction yielded the desired xanthocercin A 60 product. The 
crude material was purified via reverse phase column chromatography followed by 
PREP-TLC to insure high purity. The purified synthetic sample of xanthocercin A sample 
was analyzed at the UIC facility using 900 MHz 1HNMR and mass spectroscopy in order 
to confirm that the structure of unknown material in the lead plant was indeed 
xanthocercin A. Dr. David Lankin, NMR specialist at the UIC, confirmed that the 
isolated material from the lead plant was indeed xanthocercin A, as the spectra of our 
synthesized sample matched that of the material isolated from natural sources. 
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Methoxy-butesuperin B 
A second component, presumed to be methoxy-butesuperin B 61 (figure 14) was 
also isolated from the leadplant extract. This previously unreported compound appeared 
similar to xanthocercin A 60 in its spectral characteristics; however, insufficient amounts 
of pure material were available in order complete unambiguous characterization. To 
confirm the proposed structure, total synthesis of methoxy-butesuperin B 61 was 
necessary.    
 Due to the similarity in the overall structure and functional groups of xanthocercin 
A 60 and methoxy-butesuperin 61, the synthetic approach toward constructing the latter 
compound could follow similar methods as in the previously described reactions used to 
synthesize xanthocercin A.  
 
 
Figure 14. Structure of the xanthocercin A 60 and proposed structure of methoxy-
butesuperin 58 
 
 The key differences in the structure were the lack of a hydroxyl group on the 3-
aryl ring of the chromenone system, and the presence of a methoxy group on the 6-
position of the chromenone ring. This different oxidation pattern required the rare starting 
material methoxy pyrogallol 80, which was prepared by Dr. Klein. This tetra-oxy 
derivative 80 was used to couple with the commercially available 4-methoxy phenyl 
acetic acid 81 (Scheme 32).  
HO
O
O
O O
O
OH
60 61
HO
O
O
O O
O
OH OH
O
O O
O O
	 36	
 Ring systems containing four oxygen functional groups are uncommon to use in 
the synthetic reactions. According to the data provided by Scifinder.cas.org “methoxy 
pyogallol” 80 was mentioned in the literature twice, while “pyrogallol” 71 was cited 2500 
just as a reactant and reagent. The shortage of references suggests some challenges in the 
desire and use of these highly electron-rich species. Hydroxy and methoxy groups are 
strong electron donors, which activate ortho-para positions for electrophilic aromatic 
substitutions (Figure 15). 
 
Figure 15. Resonance structures of phenol demonstration ortho-para activation of the 
ring  
 
 Since there are two hydroxy groups donating to C-4 and hydroxyl with methoxy 
group donating to C-3, C-4 should be more activated to react with 4-methoxyphenyl 
acetic acid 81 (Scheme 32). However, the additional presence of methoxy group on the 
pyrogallol ring 80 complicates the reactivity of the compound. The same reaction 
conditions that yielded relatively pure chromenone 70 with pyrogallol 71, yielded low 
amounts of desired product with methoxy pyrogallol 80. A significant amount of 
unreacted starting material was left. Therefore, modifications were tested to find suitable 
reaction conditions (Table 4).  
Scheme 32. Reaction of methoxy pyrogallol and 4-methoxy phenyl acetic acid 
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Table 4. Reaction conditions to synthesize chromenone 82 
Entry Reactant  Condition Conclusion 
1 
Methoxy pyrogallol 80 
Acid 81 
BF3Et2O 
1.5h at 80-85˚C DR-II-75 
Incomplete reaction with presence 
of starting material and desired 
product. 
2 
Methoxy pyrogallol 80 
Acid 81 
BF3Et2O 
1.5h at 80-85˚C DR-II-77 
Reaction was monitored every 15 
minutes with HPLC, mostly product 
was observed after 1h of reaction  
3 
Methoxy pyrogallol 80 
Acid 81 
BF3Et2O 
Room 
temperature, 
Over night  
DR-II-79 
Mostly unreacted starting material 
according to HPLC 
4 
Methoxy pyrogallol 80 
Acid 81 
BF3Et2O 
Microwave 
125˚C for 5 min  
DR-II-81 
Presence of product and new 
impurities  
5 
Methoxy pyrogallol 80 
Acid 81 
BF3Et2O 
115˚C oil bath 
for 15 min  
DR-II-83  
Starting materials are still present, 
but the most optimal condition 
which yielded majority of desired 
product  
  
 The optimal conditions identified in this study were described in entry 5 (Table 
4). The reaction was monitored every 10 minutes by HPLC for over an hour at 115˚C, to 
monitor the formation of the product and impurities. With the increase of reaction time, 
the ratio of impurities to desired product increased, as more signals for side-products 
appeared on the spectrum. The obtained methoxy-chromenone 82 was used to continue 
the sequence by reacting with TCT to yield methoxy-isoflavone 84 (Scheme 34).  
Scheme 34. Methoxy-isoflavone 84 formation reaction  
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 TCT was used since it yielded higher amounts of methoxy-isoflavone 84 
compared to the reaction with DMF-DMA (Table 3). Both reagents make the same key 
intermediate 83. Therefore, an explanation of the difference in reactivity is due to the 
mechanistic differences in early steps of the reactions.  
Scheme 35. Proposed mechanism for the formation of methoxy-isoflavone 84 using TCT 36  
 
 
Scheme 36. Proposed mechanism for the formation of methoxy-isoflavone 84 using 
DMF-DMA 
 
 
 Initially, the environment in which both reactions occur is different. The reaction 
in TCT with the presence of BF3OEt2 is under acidic condition. Boron trifluoride diethyl 
etherate coordinates to the carbonyl group of isoflavone leading to formation of a 
boronate enol complex. The reaction with DMF-DMA proceeds in the absence of acid 
catalyst, which can explain possible difference of reactivity. However, since the reactions 
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for this project were done without BF3OEt2 and had similar outcomes the difference in 
reactivity is due to other factors.  
 A possible explanation is the nature of reactive nitrogen cation species. In the 
reaction of DMF-DMA after addition of nitrogen cation the leaving group from 
tetrahedral intermediate is methoxy group, which is relatively bad leaving group 
compared with the chloride in the TCT reaction.  
 The final step of the methoxy-butesuperin B synthesis was the oxidative coupling 
of methoxy-isoflavone 84 and sinapyl alcohol 68 (Scheme 37).  
Scheme 37. Oxidative coupling of methoxy-isoflavone 84 and sinapyl alcohol 68 
 
 The reaction procedure was followed as before, interestingly the reaction mixture 
yielded two diastereomers, (+)-cis and (+)-trans, in a 1:2 mixture respectively. An 
isomerization reaction using potassium carbonate was carried out to convert the higher 
energy cis diastereomer into a lower energy trans compound via a ring opening/closing 
deprotonation (Scheme 38).  
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Scheme 38. Isomerization reaction to yield trans methoxy-butesuperin B 61 
 
 
2.4 Conclusion 
Both xanthocercin A and its derivative, methoxy-butasuperin B, were successfully 
synthesized. Xanthocercin A pure material was sent to the UIC for the molecular 
structure confirmation. Dr. David Lankin, at the UIC confirmed that the structure of 
synthesized xanthocercin A 60 matches the structure of the isolated molecule from the 
leadplant. Methoxy-butesuperin B was also synthesized by oxidative coupling between 
methoxy-isoflavone 84 and sinapyl alcohol 68. Methoxy-butesuperin B, currently, is 
being re-purified prior to its final analysis at the UIC to determine wheater the assigned 
structure matches the synthesized methoxy-butesuperin B.  
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3.0 Experimental Section 
General remarks  
 
 Unless otherwise noted all reactions were performed in oven-dried glassware 
under nitrogen atmosphere. Tetrahydrofuran (THF), dimethylformamide (DMF), toluene, 
and dichloromethane (DCM) anhydrous solvents that were used are DriSolv from EMD 
Millipore Corporation. Commercial reagents were used as obtained unless otherwise 
specified.  
 Reactions were monitored by standard thin-layer chromatography (TLC) 
techniques using EMD silica gel 60 F254 pre-coated plates (0.25 mm thickness) or 
HPLC. Following the run, TLC plates were visualized under UV light.   
 Synthesized compounds were analyzed using proton or carbon nuclear magnetic 
resonance (1H NMR or 13C NMR) onVarian Inova 400mHz spectrometer using TMS as 
the internal standard and chloroform as a solvent, unless specified otherwise. The values 
for chemical shifts (∂) reported in parts per million and coupling constants (J) in hertz. 
HPLC spectra were recorded on a Shimadzu 10EZ instrument. Purification of samples 
was done using normal and reverse phase columns on Biotage Isolera Dalton.   
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3.1 Procedures: Citreamicin θ A model  
1,4-Bis(trimethylsilyl)-1,3-butadiyne (32) 
 
 
TMEDA (7.61ml, 51mmol) was added to a room temperature solution of CuI (5.0559 g, 
51 mmol) in acetone (90 ml). The flask was opened to air, at which point the color 
changed from yellow to dark green-blue and was stirred for 30 min. Separately, oxygen 
gas was bubbled into the flask of a room temperature (trimethylsilyl) acetylene (7.04 ml, 
51 mmol) solution in acetone (60ml). The copper catalyst was added in increments of 
1.5-3 ml over the duration of one hour. The reaction mixture was concentrated and the 
resulting crude mixture was extracted with 3N HCl (3 x 5 ml), brine (3 x 10 ml) in 
pentane (3 x 10ml). Recrystallization: to the heated mixture in MeOH (40 ml) was added 
3N HCl (0.4 ml). Once all the solid was dissolved, cool H2O (3 ml) was added dropwise. 
The product was isolated using vacuum filtration to provide 3.2g (65%) of alkyne 32, a 
grey crystalline material: Rf 0.53 (hexane); 1H NMR (400 MHz, CDCl3) ∂ 0.189 (s, 18H); 
13C NMR (400 MHz, CDCl3) ∂ 76.9, 77.2, 77.5, 86.1, 88.2. Data identical to previously 
reported material.24 
 
 
1,3-Butadiynyl(trimethyl)silane (29) 
 
 
 
MeLi (0.8 ml, 1.28 mmol) was added to a room temperature solution of butadiyne 32 
(250 mg, 1.28 mmol) in anhydrous diethyl ether (4 ml) for 2h. The reaction mixture was 
cooled to 0˚ C and carefully quenched with saturated aqueous NH4Cl. The layers were 
separated and the aqueous layer was extracted with Et2O (3 x 5 ml) and brine (3 x 5 ml). 
The product was isolated using vacuum distillation. The combined layers were dried with 
MgSO4 and concentrated using a rotary evaporator to yield 0.117 g (75% of crude 3:1 
mixture of product to starting material) colorless liquid, which was purified by vacuum 
distillation; 1H NMR (400 MHz, CDCl3) ∂ 0.19 (s, 9H), 2.1 (s, 1H). Data identical to 
previously reported material.42  
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2-bromo benzyl alkyl (34) 
 
 
1-(trimethylsilyl)propyne 27 (1g, 8.9 mmol) was added to a solution of anhydrous THF 
(45 ml). The reaction mixture was cooled to -78 ˚C, a solution of n-BuLi (0.8g 2.51 molar 
in hexanes) was added dropwise over 5 min time interval. The mixture was warmed to 0 
˚C for 15 min, then cooled again to -78 ˚C. A solution of 2-bromo-benzyl bromide 28 
(3g, 12 mmol) in anhydrous THF (10 ml) was added into the reaction flask through an 
addition funnel slowly over 10 min, which caused the disappearance of the yellow color 
of the solution. The reaction was warmed to a room temperature and quenched with 
saturated aqueous NaHCO3. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 10 ml), water (3 x 10 ml), and brine (3 x 10 ml). The 
combined layers were dried with over Na2SO4. Purification by FLASH chromatography 
(100% hexane) gave 3.3 g (97%) of 2-bromo benzyl alkyl 34: Rf 0.21 (hexane); 1H NMR 
(400 MHz, CDCl3) ∂ 0.13 (s, 9H), 2.52 (t, J=7.4, 2H), 2.94 (t, J=7.4, 2H) , 7.21 (t, J=7.2, 
1H), 7.21 (m, 2H), 7.49 (d, J=8, 1H); 13C NMR (400 MHz CDCl3) ∂ 0.000, 20.20, 35.16, 
85,45, 105.9, 124.2, 127.1, 127.9, 130.8, 132.6, 139.4.  
 
 
 
2-iodo(triisopropylsilyl-1-butyne) (40) 
 
 
 
 
 
n-BuLi (0.78 ml, 1.97mml) was added to a -78˚C solution of 1-triisopropylsilyl-1-
propyne 38 (0.48 ml, 1.98 mmol) in anhydrous THF (6ml) under dry nitrogen. The 
reaction mixture was warmed to the 0˚C for 20 min. A solution was cooled to -78˚C and a 
mixture of benzyl bromide 36 (516 mg, 1.73 mmol) in THF (9ml) was added to the 
reaction flask dropwise. The reaction was kept at -78˚C for an hour then slowly warmed 
to room temperature and left to stir overnight and quenched with saturated aqueous 
NH4Cl. The layers were separated and the aqueous layer was extracted with hexane (3 x 
10 ml). The combined layers were dried with over Na2SO4 and concentrated using a 
rotary evaporator. Purification was done by alkylation reaction to isolate TIPS iodide 40. 
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Alkylation reaction to purify 2-iodo(triisopropylsilyl-1-butyne) (40)  
 
 
 
 
 
Pyrrolidine 41 (69.9µl, 0.84mmol) was added to a 3:1 mixture of iodo butyne 40 and 2-
iodobenzylbromide 36 (100mg, assumed 0.16mmol) in acetonitrile. A condenser (0˚C) 
with a nitrogen line was placed over the flask and heated to 80˚C. Reaction time 35 min. 
The sample was concentrated and extracted with hexane (3 x 5 ml); combined organic 
layers were washed with aqueous HCl (10%) (1 x 10). The crude mixture was filtered 
through a silica gel plug to yield 0.227 g (40%) of a solid 2-iodobutyne 40: Rf 0.34 
(100% hexane); 1H NMR (400 MHz, CDCl3) ∂ 1.05 (s, 18H), 2.56 (t, J= 7.3, 2H), 2.95(t, 
J=7.2, 2H), 6.9 (t, 1H), 7.79 (d, 7.8, 1H). 
 
 
TIPS-TMS- trialkyne (43) 
 
 
 
Iodo butyne 40 (24.2 mg, 0.058mmol), butadiynyl-TMS 29 (10.6 mg, 0.087 mmol), 
Pd(PPh3)4 (4.1mg, 0.035 mmol), CuI (1 mg, 0.006 mmol) and diisopropylamine (0.3 ml) 
were measured into a 4 ml vial and purged with nitrogen gas. After three hours, 
butadiynyl-TMS 29 (10µl), CuI (1.1 mg) and Pd(PPh3)4  (3.6 mg) were added to the 
reaction flask. The reaction was allowed to stir at room temperature for 24 h. The 
reaction mixture was concentrated and diluted with hexane to be the filtered through a 
plug of silica gave 15 mg (84%) of TIPS-TMS trialkyne 43, a light-brown solid: Rf 0.21 
(100% hexane); 1H NMR (400 MHz, CDCl3) ∂ 0.24ppm (s, 9H), 1.01 (s, 18H), 2.62 (t, 
J=7.2, 2H), 3.00 (t, J=7, 2H), 7.16 (t, J=6.3, 1H), 7.45 (d, J=8.2, 1H); 13C NMR (400 
MHz, CDCl3) ∂ 11.4, 18.8, 21.1, 29.9, 33.9, 75.4, 81.5, 87.9, 91.3, 107.9, 120.9, 126.5, 
129.4, 129.6, 133.736, 144.3, 165.2. 
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Terminal TIPS-alkyne (46)  
 
 
 
 
TIPS-TMS- trialkyne 43 (5.7 mg , 0.014mmol) was combined with potassium 
bicarbonate (1.4 mg , 0.014 mmol) in methanol (0.1 ml) and stirred at room temperature 
for 2 hours. The reaction mixture was concentrated, and filtered though a cotton ball 
rinsing with hexane. The reaction yielded 2.6 mg (76%) of dark solid: Rf 0.18 (100% 
hexane); 1H NMR (400 MHz, CDCl3) ∂ 1.01 (s, 18H), 2.54 (s, 1H), 2.62 (t, J=7.1, 2H), 
3.01 (t, J=7.1, 2H), 7.18 (t, 1H), 7.48 (d, J=7.4, 1H). 
 
 
tri-alkyne (54) 
 
 
 
 
di-TMS-alkyne 24 (12.8 mg, 0.043 mmol) was combined with potassium bicarbonate 
(8.6 mg, 0.086 mmol) in methanol (0.43 ml) and stirred at the room temperature for 2 
hours. The reaction mixture was concentrated and filtered through a cotton ball rinsing 
with hexane. The reaction yielded 4.9 mg (65%) of dark solid: Rf  0.12 (100% hexane); 
1H NMR (400 MHz, CDCl3) ∂ 1.98 (t, J=2.5,1H), 2.54 (t, 2H), 3.02 (t, J=7.4, 2H), 7.19 (t, 
J=6.5, 1H), 7.50 (d, J=7.4, 1H). 
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3.2 Procedures: Xanthocercin A 57 and methoxy-butesuperin B 58 
 
7,8-dihydroxy-3-(methoxyphenyl)-4H-chromen-4-one (70)36 
 
 
 
 
A mixture of pyrogallol 71 (0.15 g, 1.19 mmol), 3-hydroxy-4-methoxyphenylaceticacid 
72 (0.216 g, 1.19 mmol), and BF3·Et2O (0.448 ml, 3.57 mmol) was stirred at 85 °C for 2 
h under N2 with an air condenser. The mixture was then poured into an aqueous 10% 
solution of NaOAc (18 mL) and allowed to stand for 4 h. The layers were separated and 
the aqueous layer was extracted with EtOAc (3 x 10 ml). Combined organic layers were 
washed with water (3 x 5 ml) and brine (3 x 5 ml). The crude amorphous solid was 
recrystallized in hot methanol to obtain 0.172 mg (50%) of a green solid: Rf 0.46 (10% 
MeOH in DCM), 0.61 (50 % of MeOH in DCM); 1HNMR (400 MHz, DMSO) ∂ 3.72 (s, 
3H), 4.08 (s, 2H), 6.38 (d, J=8.8, 1H), 6.67 (m, 2H), 6.82 (d, J=8, 1H), 8.61 (s, 1H), 8.92 
(s, 1H), 10.1 (s, 1H), 12.6 (s, 1H). 
 
 
 
7,8-Dihydroxy-3-(4-methoxy-3-hydroxyphenyl)-3H-chromen-4-one (69)36 
 
 
Chromenone 70 (0.2g, 0.69 mmol) in DMF (1 mL) was added dropwise to a mixture of 
2,4,6-Trichloro-1,3,5-triazine (TCT) (0.191 g, 1.0 mmol) in DMF (0.228 mL). The 
reaction mixture was heated to 60 °C for 30 min and poured into a boiling HCl (10%) to 
be slowly cooled to the room temperature. The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 7 ml) and the combined organic layer was dried over 
Na2SO4. The crude material was recrystallized in ethyl acetate/hexane to yield 0.103 g 
(50 %) of yellow foam-solid: Rf 0.32 (10% MeOH in DCM); 1HNMR (400 MHz, 
DMSO) ∂ 3.77 (s, 3H), 6.93 (m, 3H), 7.03 (s, 1H), 7.44 (d, J= 8.8, 1H), 8.31 (s, 1H). 
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3,5-Dimethoxy-4-hydroxycinnamic acid, 4-Hydroxy-3,5-dimethoxy-cinnamic acid 
(75) 
 
 
Malonic acid 74 (2.5 g, 23.9 mmol) and aniline (130 µL, 1.4 mmol) were added to a 
solution of syringaldehyde 73 (2g, 10.9 mmol) in pyridine (4.9 mL). The mixture was 
heated to 60 °C overnight. The hot reaction mixture was poured onto a mixture of ice (10 
g) and concentrated HCl (6.6 mL) then stirred for 30 minutes. The resulting solid was 
collected by filtration to obtain 2.2 g (91%) of white crystalline solid: 1HNMR (400 
MHz, DMSO) ∂ 3.80 ppm (s, 6H), 6.43 (d, J= 15.9, 1H), 6.99 (s, 2H), 7.50 (d, J= 15.9, 
1H), 8.93 (s, 1H), 12.16 (s, 1H). Data identical to previously reported material.39 
 
 
 
Methyl 3-(4-hydroxy-3,5-dimethoxyphenyl)acrylate (76) 
 
 
Thionyl chloride (COCl2) (0.53 g, 4.46 mmol) was added dropwise to methanol (10 mL) 
at 0 °C. The mixture was allowed to stir for 15 minutes. Sinapic acid 75 (0.93 g, 4.46 
mmol) was added and the reaction mixture was heated to 60˚C for 1 hour with an air 
condenser. The mixture was cooled to a room temperature and the product precipitated 
from the reaction solution. The mixture was then carefully concentrated to remove most 
of the methanol and filtrated to provide 0.849 g (80%) of beige solid: 1HNMR (400 MHz, 
CDCl3) ∂ 3.80  (s, 3H), 3.92 (s, 6H), 5.78 (s, 1H), 6.29 (d, J= 15.9, 1H), 6.77 (s, 2H), 7.59 
(d, J=16, 1H). Data identical to previously reported material.39 
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Silver (I) Oxide43  
 
 
 
The silver oxide was prepared by stirring 98% sodium hydroxide (1.99g, 0.05 moles) in 
water (50 ml) at 85˚C. The silver nitrate (8.5 g, 0.05 moles) was combined with water (50 
ml) at 80˚C. The solution of sodium hydroxide in water was transferred into the flask 
with silver oxide, while hot. The precipitate was collected using vacuum filtration and 
dried for 4 hours in the vacuum oven to yield 9.9 g (86%) of silver oxide a dark brown 
powder.  
 
 
4-[(E)-3-hydroxyprop-1-enyl]-2,6-dimethoxyphenol (68)  
 
 
 
n-BuBr (107 µl, 1 mmol) was added dropwise to a solution of LiAlH4 (1.0 ml, 1.0 mmol) 
in THF (3.2 mL) at 0 °C, the solution was stirred at room temperature for 2 hours. The 
reaction mixture was cooled to -78 °C and methyl sinapate 76 (160 mg, 0.67 mmol) in 
THF (3.0 mL) was added dropwise. The mixture was warmed to a room temperature and 
stirred for 2 hours. The reaction was quenched by slow addition of EtOAc (0.4 mL), 
which followed by the addition of water (3 ml) until gas evolution stopped. A solution of 
saturated aqueous NH4Cl (2.5 ml) was then added until a semi-solid paste formed. The 
layers were separated and the clear/colorless organic layer was decanted and the 
remaining paste was re-extracted with EtOAc (3 x 7 ml). Organic layers were combined 
and washed with brine. The sample was concentrated in to give 0.127 g (85%) of sinapyl 
alcohol, light yellow oil: Rf 0.18 (50% ethyl acetate in hexane); 1HNMR (400 MHz, 
CDCl3) ∂ 3.90 (s, 6H), 4.31 (t, J= 5, 2H), 5.56 (s, 1H), 6.26 (dt, J= 15.8, 1H), 6.50 (d, 
J=15.9, 1H), 6.63 (s, 2H). 
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2,3-trans-3-(4-hydroxy-3,5-dimethoxyphenyl)-8-(3-hydroxy-4- methoxyphenyl)-2-
hydroxymethyl-2,3-dihydro-7H-1,4-dioxino[2,3-h]chromen-7- one35 (60) 
 
 
 
 
Isoflavone 69 (0.14 g, 0.47 mmol) and sinapyl alcohol 68 (98 mg, 0.47 mmol) were 
dissolved in a mixture of anhydrous toluene (50 ml) and methanol (35 ml). Silver (I) 
oxide  (0.11 g, 0.47 mmol) was added to the reaction mixture, which was stirred at room 
temperature for 24 h. Filtration through celite and evaporation gave a crude material 
which was purified by normal phase, and PREP-TLC plate to obtain pure sample:  
1HNMR (400 MHz, Acetone) ∂ 3.58 (s, 3H), 3.87 (s, 6H), 4.37 (m, 2H), 5.16 (d, J=7.8, 
1H), 6.88 (s, 2H), 7.00 (d, J=8.4, 1H), 7.07 (d, J=9, 2H), 7.17 (s, 1H), 7.72 (d, J=9, 1H), 
8.29 (s, 1H).  
 
 
Methoxy-chromenone (82) 
 
 
 
 
A mixture of methoxy parogallol 80 (3.01 mmol), 4-methoxyphenylaceticacid 81 (3.01 
mmol), and BF3·Et2O (9.03 mmol) was stirred at 115 °C for 15 min under dry N2 with an 
air condenser. The reaction mixture was then decanted into a 10% aqueous solution of 
NaOAc (18 mL) and allowed to stand for 4 h.  The layers were separated and extracted 
with EtOAc (3 x 15 ml), water (3 x 5 ml), and brine (3 x 5 ml). Combined organic layers 
were dried with MgSO4 and concentrated by rotary evaporation. Normal phase 
chromatography (65% ethyl acetate, hexane) was performed to obtain 0.347g (38%) of 
methody-chromenone 82, viscous black oil: Rf 0.16 (65% ethyl acetate in hexane); 
1HNMR (400 MHz, Acetone) ∂ 3.8 (s, 3H), 3.87 (s, 3H), 4.28 (s, 2H), 6.91 (d, J=8.6, 
2H), 7.18 (s, 1H), 7.30 (d, J=8.4 2H). 
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Methoxy-isoflavone (84) 
 
 
 
To a mixture of 2,4,6-Trichloro-1,3,5-triazine (TCT) (0.236 g, 1.28 mmol) in DMF 
(0.281 mL) added chromenone 82 (0.26 g, 0.85 mmol) in DMF (1.3 mL), dropwise. The 
reaction mixture was heated to 60 °C for 60 min and poured into a boiling HCl (10%) to 
be slowly cooled to the room temperature. The layers were separated and the aqueous 
layer was extracted with EtOAc (4 x 5 ml) and the combined organic layers were dried 
over Na2SO4 and concentrated by rotary evaporation The reaction yielded 0.20 g (75 %) 
of yellow solid: Rf 0.26 (65% Ethyl acetate/hexane); 1HNMR (400 MHz, Acetone) ∂ 3.86 
(s, 3H), 3.96 (s, 3H), 7.00 (d, J=8.4, 2H), 7.21 (s, 1H), 7.59 (d, J=8.4 2H), 8.25 (s, 1H). 
 
 
 
Methoxy- butesuperin B (61) 
 
 
 
Isoflavone 84 (0.147 g, 0.42 mmol) and sinapyl alcohol 68 (89 mg, 0.42 mmol) were 
dissolved in a mixture of anhydrous toluene (36 ml) and methanol (25 ml). Silver (I) 
oxide  (97.3 mg, 0.42 mmol) was added to the reaction mixture, which was stirred at 
room temperature for 24 h. Filtration through celite and evaporation gave a crude 
material which was purified by normal phase, and PREP-TLC plate to obtain pure 
sample: 1HNMR (400 MHz, DMSO) ∂ 3.82 (s, 3H), 6.75 (s, 2H), 6.97 (d, J=8.8, 2H), 
7.10 (s, 1H), 7.5 (d, J=8.8, 2H), 8.49 (s, 1H), 8.59 (s, 1H). 
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